Sepsis and cancer are both leading causes of death, and occurrence of any one, cancer or sepsis, increases the likelihood of the other. While cancer patients are susceptible to sepsis, survivors of sepsis are also susceptible to develop certain cancers. This mutual dependence for susceptibility suggests shared biology between the two disease types. Earlier work in our laboratory had revealed cancer-related pathway to be up-regulated in Septic Shock (SS), an advanced stage of sepsis. In the present study, we performed comprehensive genome-scale analysis of published human transcriptome datasets from septic shock and 17 cancer types. We identified a total of 66 pathways perturbed in both septic shock and cancer. Based on enrichment scores of these pathways, some cancers were observed to be similar to sepsis (Sepsis Like Cancers -SLC group) but not others. SLC group consisted of malignancies of the gastrointestinal tract (liver, oesophagus, stomach, head and neck and biliary system) which are associated with infection. SLC group showed similar direction of change in gene expression as in septic shock while the malignancies of kidney, lung and uterus showed disagreement. The SLC group shared a large number of up-regulated pathways with SS, possibly representing the theme of dysregulated host response to infection. Notably, Galactose metabolism and p53 signalling pathways were significantly up-regulated in these cancer types along with septic shock group. This study highlights the complexity of the cancer transcriptome when viewed through the lens of septic shock.
Introduction
Sepsis is a potentially life-threatening complication caused by dysregulated host response to infection, often leading to organ failure and death. Estimated global burden of sepsis is more than 30 million people every year with 5 million deaths [1] . Newborns and children are more vulnerable with estimated incidence of 3 and 1.2 million, respectively [2] . Septic shock is the advanced stage of sepsis with metabolic dysregulation and uncontrolled hypotension. It is evident now from several epidemiological studies that sepsis and cancer are associated. Liu et al.(2018) [3] conducted an association study between sepsis and ensuing risk of cancer in elderly adult population of United States, and found that the former is significantly associated with increased risk for many cancers including chronic myeloid leukemia (CML), myelodysplastic syndrome, acute myeloid leukemia (AML), cancers of cervix, liver, lung, rectum, colon. Another association study revealed 2.5 fold increased risk of sepsis in survivors of cancer in community-dwelling adults (the risk is increased up to 10 times in hospitalized cancer patients) [4] . Co-occurrence of cancer with sepsis is associated with higher mortality than sepsis alone without cancer [5] . On the other hand, sepsis is a common cause of death in critically ill patients with cancer, with high ICU and hospital mortality [6] , [7] . Analysis of data from the past two decades revealed increasing trend in the incidence of postoperative (related to major cancer surgeries) sepsis [8] . There are previous reports on molecular changes in sepsis and cancer. Bergenfelz et al. (2012) [9] reported that Wnt5a induces immunosuppressive phenotype of macrophages in sepsis and breast cancer patients. HMGB1, a key late inflammatory mediator of systemic inflammatory response syndrome associated with bacterial sepsis, is also implicated in tumorigenesis and disease progression [10] . Muscle wasting, observed in patients with cancer, severe injury and sepsis, is associated with increased expression of several genes, particularly transcription factors and nuclear cofactors, regulating different proteolytic pathways [11] . CD11b/CD18 expression in monocytes has been proposed as a biomarker of infection in cancer patients [12] . These studies focused on the gene as the functional unit of analysis. On the other hand, a gene set or pathway represents coordinated molecular activity and captures higher-order functional unit in a tissue or cell. Pathway-level analysis allows detection of a cumulative signal that is not accessible at the gene-level. We did not find any report in literature about pathway-level comparative analysis between sepsis and cancer. In the present study, we have performed unbiased analysis of SS and cancer datasets to discover shared patterns of pathway perturbation between cancer and SS.
Materials and methods
Gene expression data for 17 different human cancers were retrieved from TCGA database (https://portal.gdc.cancer.gov/) on July 5, 2018. For each tissue, TCGA project code was provided in the search field and RNA-seq data for paired samples (case-control) were downloaded. Likewise, transcriptome data of human septic shock (SS) were retrieved from Gene Expression Omnibus (GEO) database on April 10, 2019. Retrieved expression data were log2-transformed. Gene Set Enrichment Analysis (GSEA) on expression data of both cancer and SS was performed as published earlier [13] . Briefly, enrichment score (ES) for each pathway was calculated by dividing the sum of the gene-level log-fold changes with the square root of the pathway size. This provided a pathway-level score which was highly positive for up-regulated pathways and highly negative for the down-regulated pathways. Significance of the observed score (ES) was estimated in the following manner. By scrambling the case/control labels, new data were simulated and ES recalculated for each simulation. When repeated over 2/27 many (i.e., 10000) iterations, this generated the null distribution of the simulated ES for each pathway. Fraction of the ES null distribution that was more extreme than the observed ES was estimated to be the p-value associated with the pathway [14] . Selection of the transcriptome data sets and analysis workflow leading to the final list of significant pathways are described in Figure 1 . The study characteristics of the data sets are listed in Table 1 . We performed network analysis using each pathway as node and shared genes between pathways as their connecting edges. Firstly, a background network was constructed by including all the pathways (KEGG [15] ) with overlapping gene memberships, i.e., for a pathway to be included, it must share at least 5% of the total number of genes with another pathway. In this network, each pathway was considered a node, and the edge between two nodes suggested overlap between the two pathways. The nodes in the network were coloured according to the disease-group in which the node (pathway) was perturbed: SLC (sepsis-like cancer), CA-only (uniquely cancer) or both. All programming was done in the R programming language (R core team 2013) [16] . The code is available on request.
Results
Out of 290 KEGG pathways, 90 were significantly perturbed in SS group (p < 0.01). Hierarchical clustering on combined cancer and sepsis data sets for these 90 pathways revealed two groups of cancers: which segregated with sepsis (sepsis-like cancer, or SLC) and which did not segregate with SS (uniquely cancer, or CA) ( Figure 2 ). Out of 17 cancer types, 11 uniquely cancer studies were grouped (CA group) under the first clade of the heatmap. The CA group comprised of BLCA, BRCA, COAD, KICH, KIRP, LUAD, LUSC, PRAD, READ, THCA and UCEC. Second clade was formed with other cancer studies (LIHC, CHOL, KIRC, HNSC, ESCA and STAD, together termed the SLC group) and 6 SS studies. Of the 90 pathways, we further selected those pathways which were significantly perturbed in at least 80% of one or both of the cancer groups (SLC and CA) leading to retention of 66 pathways ( Figure 3 ) which were subjected to further analysis. Many of the 66 SS-associated pathways were significantly perturbed in cancer including KICH (66), CHOL and LIHC (64 each), HNSC (63), STAD (60), ESCA (57), LUSC (51), KIRC (50). While the SLC group showed more than 75% of the selected pathways to be associated with SS, many of the CA group cancers showed less association with these pathways. For example, except KICH (66) and LUSC (51), most CA group cancers had either low number of associated pathways -THCA (21), PRAD (12) , READ (10) -or showed intermediate association, such as BRCA (49), UCEC (45), COAD (39), KIRP (33), LUAD (33), BLCA (30) and THCA (21) . In general, the pathways were up-regulated in the SLC group (in the same direction as SS, with more intensity) and down-regulated (in a direction opposite to SS) in the CA group. Two cancer associated KEGG pathways were found to be differentially perturbed in both cancer and SS such as Pathways in cancer (Supplementary Figure  S1) and Transcriptional mis-regulation in cancer (Supplementary Figure S2) .
Interestingly, all three down-regulated pathways (Ribosome biogenesis in eukaryotes, Antigen processing and presentation, and Primary immunodeficiency) in SS group were up-regulated in SLC group. In order to ascertain relative importance of each pathway, we performed network analysis. We considered each pathway as a node and its connection with the next node based on sharing of genes between them. If two pathways shared at least 5% of genes common among themselves, then they were considered connected. In this way, we generated a network of KEGG pathways with 244 nodes (each node being a KEGG pathway) and 5304 edges. The overall property of the network was assessed by looking at the degree distribution of the nodes ( Figure 4) . As expected of all biological networks, there are many nodes with few edges between them and some nodes with many edges ( Figure 5 ). By colouring the three principal groups of pathways with three different colours, it is revealed that the SLC-only nodes (coloured red) are located in the core of the network, while the other nodes are more peripheral. Of the pathways detected as significant in this analysis, some stand out for their biological and clinical relevance. These are described below. Lysosome: Lysosomal pathway was found to be differentially perturbed in both SS and SLC (Supplementary Figure S3) . Lysosomes are membrane-bound catabolic organelles that maintain cellular homeostasis. Marked changes in composition and function of lysosomes can be observed in disease conditions. Sepsis and cancer induced changes in lysosomes are pronounced and also share commonality between them. Muscle wasting is one of the most common phenomenon in critically ill patients with sepsis. Apart from proteasome system, lysosome pathway also plays important role in protein degradation [17] and degradation of autophagosomes generated after the onset of sepsis, has been implicated in cancer cachexia leading to muscle wasting in cancer [18] . Interestingly cancer cells are known to have increased biogenesis of lysosomes with different membrane composition, enhanced expression, activity and secretion of lysosomal enzymes [19] . Besides, Lysosomes are now considered as hub of metabolic signaling [20] . In our study, all members of SLC (except KIRC with non-significant positive ES) and SS groups have positive ES along with the UCEC, KIRP, THCA, BLCA and BRCA of the CA group ( Figure 3 ). Ma et al. 2015 [21] , reported upregulation of lysosome pathway in SS. Upon investigation of the pathway in the network of pathways it was revealed that lysosome pathway has the second highest (after Glycolysis/Gluconeogenesis pathway: 1599.07) betweenness value of 680.2, showing its hub-like nature in the network.
Leukocyte transendothelial migration: Leukocyte transendothelial migration pathway was found to be differentially perturbed in both SS and SLC (Supplementary Figure  S4) . Migration of leukocytes from the blood into sites of tissue injury and infection, across the vascular endothelium, is a fundamental immune response to eliminate inflammatory trigger and help in tissue repair. Leukocyte transendothelial migration pathway is significantly up-regulated in SS and SLC groups as well as THCA of CA ( Figure 3 ). However, most of cancers of CA group including BRCA, COAD, KICH, KIRP, LUAD, LUSC, PRAD and UCEC showed significant down-regulation of this pathway. Other pathways related to infection and inflammation, i.e., Galactose metabolism: Galactose metabolism pathway was found to be differentially perturbed in both SS and SLC (Supplementary Figure S11) . In humans, d-galactose is generated after breakage of lactose or catabolic event of glycoproteins and glycolipids by glycoside hydrolase enzymes (Alpha-galactosidase (α-GAL, also known as α-GAL A; E.C. 3.2.1.22)). Finally, d-Galactose is converted into many intermediate metabolites and may enter any of the carbohydrate metabolism pathways (e.g. Fructose and mannose metabolism, glycolysis, pentose phosphate pathway). However, any imbalance in galactose metabolism that increases levels of galactose or galactose 1-phosphate may lead to galactosemia. Galactosemia has been implicated in neonatal sepsis [22] , [23] . Further, high level of d-galactose is reported in cases of sepsis [24] . Galactose metabolism pathway is also up-regulated in SLC (except STAD) and SS groups. Likewise, we found this pathway up-regulated in BLCA, KIRP, LUAD, LUSC and UCEC while down-regulated in COAD, KICH, PRAD and READ in CA group. UDP-galactose (mainly derived from d-galactose via Leloir pathway) provide galactosyl entity for the biosynthesis of glycolipids and glycoproteins that play important role in receptormediated signalling, cell-cell recognition and metastasis in cancer cells [25] .
Bladder cancer: Bladder cancer pathway was found to be differentially perturbed in both SS and SLC (Supplementary Figure S12) . Notably, bladder cancer pathway is up-regulated in all the diseases of SLC and SS groups and many diseases of CA group including BLCA, BRCA, COAD, LUAD, LUSC, READ, THCA and UCEC as well.
p53 signaling pathway: p53 signaling pathway was found to be differentially perturbed in both SS and SLC (Supplementary Figure S13) . Stress signals (i.e. oxidative stress, DNA damage, oncogene activation etc.) induce p53 activation leading to enhanced transcription of p53-regulated genes, resulting in DNA damage repair, cell cycle arrest, cellular senescence or apoptosis. Like bladder cancer pathway, p53 signaling pathway is also significantly up-regulated in all disease types of SLC, SS and CA groups (except KICH and PRAD).
Ribosome biogenesis in eukaryotes: Ribosome biogenesis in eukaryotes was found to be differentially perturbed in both SS and SLC (Supplementary Figure S14) . Ribosomes are sites of protein synthesis in the cell, and their biogenesis is vital for the cell growth and division. Interestingly, we found down-regulation of ribosome biogenesis pathway in all SS datasets, but up-regulation in CA and SLC groups including BLCA, BRCA, COAD, KIRP, LUAD, LUSC, PRAD, READ and UCEC.
Discussion
Septic shock is a lethal condition with profound genome-scale change in expression. Earlier work in our laboratory had revealed cancer-associated pathways to be associated with septic shock [13] , providing motivation for comparison of the transcriptomes between SS and cancer. By comprehensive transcriptome analysis of human septic 5/27 shock at the pathway level, we sought to capture the higher-order signal in the two clinical entities (sepsis and cancer). We identified 90 pathways that were significantly perturbed and mostly up-regulated in SS. Hierarchical clustering of perturbation signals clearly segregated the cancer studies into two groups: those perturbed in the same direction as SS, i.e., up-regulated (called SLC group) and those that were perturbed in the reverse direction (called CA group). The CA group shows general down-regulation (with lesser significance) in most of the pathways compared to SLC. On the other hand, the SLC group showed similar (if somewhat accentuated) pathway gene expression profile as SS. Five out of six of the SLC group cancers belonged to that of the gastrointestinal system (head and neck, esophagus, stomach, liver and biliary system). These cancers are often associated with infection (i.e., human papilloma virus in "head and neck", H. pylori in stomach, hepatitis viruses in liver). This is of biological significance as SS is caused by abnormal host response to infection leading to systemic inflammation and organ failure, and inflammation is also a common theme in many cancers. The similar pathway signature between SS and SLC suggests common biological processes involving dysregulated host response to infection at different stages of disease pathogenesis. This has implications for management of different cancers which needs further investigation.
In conclusion, comparative transcriptomics of septic shock and cancer has revealed strong similarity of a groups of cancers (called SLC group here) with septic shock. These malignancies include many of the gastrointestinal tract that are often associated with infection. Robust up-regulation of a large number of pathways in septic shock is accentuated in the SLC cancers, which suggests a common biological theme running through these two distinct clinical entities. This is the first attempt to view the cancer transcriptome through the lens of septic shock. It is hoped that further work shall translate this result to actionable knowledge for clinical management of both cancer and septic shock.
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Supplementary Figure S1 : [Pathways in cancer hsa05200] was observed to be up-regulated in both SS and SLC.
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Supplementary Figure S6: [TNF signaling pathway hsa04668] was observed to be up-regulated in SS and SLC. CHOL   ESCA  HNSC  KIRC  LIHC  STAD  GSE13904  GSE26378  GSE26440  GSE4607  GSE8121  GSE9692   TBKBP1  IKBKE  ISG15  ATG5  ATG12  FADD  RIPK1  TRADD  IKBKG  CASP10  CASP8  SIKE1  NLRX1  DHX58  TRIM25  TRAF6  TRAF3  TRAF2  TNF  MAP3K7  AZI2  IFIH1  MAPK12  RELA  MAVS  IFNK  MAPK13  MAPK10  MAPK9  MAPK11  MAPK8  OTUD5  RNF125  PIN1  NFKBIB  NFKBIA  NFKB1  MAP3K1  IRF7  IRF3  CXCL10  IL12B  IL12A  CXCL8  IKBKB  IFNW1  IFNB1  IFNA21  IFNA5  TMEM173  IFNE  TBK1  TKFC  DDX58  DDX3X  CYLD  MAPK14  CHUK HNSC  KIRC  LIHC  STAD  GSE13904  GSE26378  GSE26440  GSE4607  GSE8121  GSE9692   CDH1  CDC42  ELMO1  BCAR1  WASL  WASF1  CBLB  CBL  CAV3  CAV2  CAV1  PIK3R3  CLTCL1  ARPC5L  ELMO3  ARHGAP10  WAS  VCL  ACTG1  SRC  SHC1  ELMO2  ACTB  RAC1  PXN  PTK2  SEPT3  SEPT11  SHC3  PIK3R2  PIK3R1  PIK3CG  PIK3CD  PIK3CB  PIK3CA  SEPT2  MET  SHC4  RHOG  RHOA  ITGB1  ITGA5  ILK  HCLS1  CTNNA3  ARHGEF26  DNM3  SHC2  GAB1  CBLC  CD2AP  PIK3R5  FN1  SEPT8  SEPT6  CTTN  DOCK1  DNM2  DNM1  SEPT1  CTNNB1  CTNNA2  CTNNA1  CRKL  CRK  SEPT12  CLTC  CLTB  CLTA  SEPT9  ARPC1A  MAD2L2  WASF2  ARPC2  ARPC1B  ARPC3  ARPC4  ARPC5 Bacterial invasion of epithelial cells hsa05100
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Supplementary Figure S13 : [p53 signaling pathway hsa04115] was observed to be up-regulated in both SS and SLC.
